e-learning
resources
Stockholm 2002
Tuesday 17.09.2002
Pulmonary pot pourri
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Treatment of pulmonary alveolar proteinosis (PAP) with administration of GM-CSF
D. S. Papakosta, J. Goutsikas, T. Kontakiotis, L. Sichletidis, D. Gioulekas, D. Patakas (Thessaloniki, Greece)
Source:
Annual Congress 2002 - Pulmonary pot pourri
Session:
Pulmonary pot pourri
Session type:
Thematic Poster Session
Number:
2834
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. S. Papakosta, J. Goutsikas, T. Kontakiotis, L. Sichletidis, D. Gioulekas, D. Patakas (Thessaloniki, Greece). Treatment of pulmonary alveolar proteinosis (PAP) with administration of GM-CSF. Eur Respir J 2002; 20: Suppl. 38, 2834
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Treatment of severe pulmonary alveolar proteinosis using inhaled GM-CSF
Source: Annual Congress 2010 - Rare diffuse lung diseases
Year: 2010
Pulmonary alveolar proteinosis
Source: Respipedia Article
Year: 2017
Inhaled GM-CSF for autoimune pulmonary alveolar proteinosis
Source: Short video statement 2020
Year: 2020
Mini-whole lung lavage to treat pulmonary alveolar proteinosis (PAP)
Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key
Year: 2020
Peculiarities of pulmonary alveolar proteinosis (PAP) due to exogenous factors
Source: Virtual Congress 2020 – Occupational exposure as a cause of respiratory disease
Year: 2020
Rituximab therapy in autoimmune pulmonary alveolar proteinosis
Source: Eur Respir J 2009; 33: 1503-1506
Year: 2009
Inhaled GM-CSF in pulmonary alveolar proteinosis (PAP) patient refractory to plasmapheresis combined with multiple whole lung lavages (WLL)
Source: International Congress 2016 – Orphan diseases I
Year: 2016
Successful treatment by GMCSF of pulmonary alveolar proteinosis relapsing after a first GMCSF course
Source: Eur Respir J 2004; 24: Suppl. 48, 670s
Year: 2004
Pulmonary alveolar proteinosis: failure of treatment by bronchoscopic lobar lavages and GM-CSF treatment in a child
Source: Eur Respir J 2003; 22: Suppl. 45, 309s
Year: 2003
Pulmonary alveolar proteinosis: from classification to therapy
Source: Breathe, 16 (2) 200018; 10.1183/20734735.0018-2020
Year: 2020
Pulmonary alveolar proteinosis (PAP) - clinical features and response to treatment by bronchofiberoscopic lobar lavage
Source: Eur Respir J 2005; 26: Suppl. 49, 541s
Year: 2005
Whole lung lavage (WLL) for patients with pulmonary alveolar proteinosis
Source: Eur Respir J 2004; 24: Suppl. 48, 670s
Year: 2004
Pulmonary alveolar proteinosis
Source: Eur Respir Rev 2011; 20: 98-107
Year: 2011
Pulmonary alveolar proteinosis
Source: Eur Respir Mon; 2009: 46: 208–224
Year: 2009
Reduced GM-CSF autoantibody in improved lung of autoimmune pulmonary alveolar proteinosis
Source: Eur Respir J 2012; 39: 777-780
Year: 2012
Efficacy of aerosolized granulocyte-macrophage colony stimulating factor (GM-CSF) in a Japanese female patient with pulmonary alveolar proteinosis (PAP)
Source: Eur Respir J 2001; 18: Suppl. 33, 221s
Year: 2001
Our cases with pulmonary alveolar proteinosis
Source: International Congress 2018 – Pitfalls in the diagnosis and management of rare diffuse parenchymal lung diseases (DPLDs)
Year: 2018
Plasmapheresis for treatment of pulmonary alveolar proteinosis
Source: Eur Respir J 2009; 33: 1220-1222
Year: 2009
Whole lung lavage efficacy in pulmonary alveolar proteinosis (PAP) is influenced by the infusion volume?
Source: International Congress 2015 – IIPs: orphan
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept